Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

ICH guideline on periodic benefit risk evaluation reporting likely in 2012

This article was originally published in SRA

Executive Summary

The International Conference on Harmonisation is working on a new efficacy-related guideline on periodic benefit risk evaluation reporting. The ICH aims to have the document ready for adoption by late 20121.

You may also be interested in...



New Zealand Mandates Labeling Changes To Warn About Certain Allergens

Sponsors of new and existing medicines in New Zealand will have to update their product labels within specified deadlines to include warning statements about certain allergens.

EMA Consults On Using Registry Studies As RWE Source

A draft EU guideline explains how disease registries can be used to supplement evidence in the pre-authorization phase and provide infrastructure for post-authorization evidence generation.

EMA Has Work Cut Out Before New Clinical Trial Portal Goes Live

Companies are being encouraged to become “early adopters” of the EU Clinical Trials Information System when it goes live in December 2021.

UsernamePublicRestriction

Register

LL1134044

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel